Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trial - PubMed (original) (raw)
Randomized Controlled Trial
. 2007 Sep 1;110(5):1130-8.
doi: 10.1002/cncr.22890.
Affiliations
- PMID: 17647221
- DOI: 10.1002/cncr.22890
Free article
Randomized Controlled Trial
Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trial
David Spiegel et al. Cancer. 2007.
Free article
Abstract
Background: This study was designed to replicate our earlier finding that intensive group therapy extended survival time of women with metastatic breast cancer. Subsequent findings concerning the question of whether such psychosocial support affects survival have been mixed.
Methods: One hundred twenty-five women with confirmed metastatic (n = 122) or locally recurrent (n = 3) breast cancer were randomly assigned either to the supportive-expressive group therapy condition (n = 64), where they received educational materials plus weekly supportive-expressive group therapy, or to the control condition (n = 61), where they received only educational materials for a minimum of 1 year. The treatment, 90 minutes once a week, was designed to build new bonds of social support, encourage expression of emotion, deal with fears of dying and death, help restructure life priorities, improve communication with family members and healthcare professionals, and enhance control of pain and anxiety.
Results: Overall mortality after 14 years was 86%; median survival time was 32.8 months. No overall statistically significant effect of treatment on survival was found for treatment (median, 30.7 months) compared with control (median, 33.3 months) patients, but there was a statistically significant intervention site-by-condition interaction. Exploratory moderator analysis to explain that interaction revealed a significant overall interaction between estrogen-receptor (ER) status and treatment condition (P = .002) such that among the 25 ER-negative participants, those randomized to treatment survived longer (median, 29.8 months) than ER-negative controls (median, 9.3 months), whereas the ER-positive participants showed no treatment effect.
Conclusions: The earlier finding that longer survival was associated with supportive-expressive group therapy was not replicated. Although it is possible that psychosocial effects on survival are relevant to a small subsample of women who are more refractory to current hormonal treatments, further research is required to investigate subgroup differences.
Trial registration: ClinicalTrials.gov NCT00226928.
Comment in
- Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trial.
Kissane D, Li Y. Kissane D, et al. Cancer. 2008 Jan 15;112(2):443-4; author reply 444. doi: 10.1002/cncr.23179. Cancer. 2008. PMID: 18058897 No abstract available.
Similar articles
- The effect of group psychosocial support on survival in metastatic breast cancer.
Goodwin PJ, Leszcz M, Ennis M, Koopmans J, Vincent L, Guther H, Drysdale E, Hundleby M, Chochinov HM, Navarro M, Speca M, Hunter J. Goodwin PJ, et al. N Engl J Med. 2001 Dec 13;345(24):1719-26. doi: 10.1056/NEJMoa011871. N Engl J Med. 2001. PMID: 11742045 Clinical Trial. - Supportive-expressive group therapy for women with metastatic breast cancer: survival and psychosocial outcome from a randomized controlled trial.
Kissane DW, Grabsch B, Clarke DM, Smith GC, Love AW, Bloch S, Snyder RD, Li Y. Kissane DW, et al. Psychooncology. 2007 Apr;16(4):277-86. doi: 10.1002/pon.1185. Psychooncology. 2007. PMID: 17385190 Clinical Trial. - A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer.
Cunningham AJ, Edmonds CV, Jenkins GP, Pollack H, Lockwood GA, Warr D. Cunningham AJ, et al. Psychooncology. 1998 Nov-Dec;7(6):508-17. doi: 10.1002/(SICI)1099-1611(199811/12)7:6<508::AID-PON376>3.0.CO;2-7. Psychooncology. 1998. PMID: 9885092 Clinical Trial. - 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
Di Saverio S, Catena F, Santini D, Ansaloni L, Fogacci T, Mignani S, Leone A, Gazzotti F, Gagliardi S, De Cataldis A, Taffurelli M. Di Saverio S, et al. Breast Cancer Res Treat. 2008 Jun;109(3):405-16. doi: 10.1007/s10549-007-9668-7. Epub 2007 Aug 9. Breast Cancer Res Treat. 2008. PMID: 17687650 Review. - Analysis of radiation therapy for the control of Merkel cell carcinoma of the head and neck based on 36 cases and a literature review.
Lawenda BD, Arnold MG, Tokarz VA, Silverstein JR, Busse PM, McIntyre JF, Deschler DG, Baldini EH, Kachnic LA. Lawenda BD, et al. Ear Nose Throat J. 2008 Nov;87(11):634-43. Ear Nose Throat J. 2008. PMID: 19006065 Review.
Cited by
- Finding my tribe: a qualitative interview study of how people living with metastatic breast cancer perceive support groups.
Mackie GM, Boyle F, Lewis S, Smith AL. Mackie GM, et al. J Cancer Surviv. 2024 Jul 24. doi: 10.1007/s11764-024-01639-7. Online ahead of print. J Cancer Surviv. 2024. PMID: 39048845 - Professionally led support groups for people living with advanced or metastatic cancer: a systematic scoping review of effectiveness and factors critical to implementation success within real-world healthcare and community settings.
Li Z, Laginha KJ, Boyle F, Daly M, Dinner F, Hirsch P, Hobbs K, Kirsten L, Mazariego C, McAuley R, O'Brien M, O'Reilly A, Taylor N, Tobin L, Lewis S, Smith AL. Li Z, et al. J Cancer Surviv. 2024 Jan 8. doi: 10.1007/s11764-023-01515-w. Online ahead of print. J Cancer Surviv. 2024. PMID: 38191752 Review. - Integrative Oncology Approaches to Reduce Recurrence of Disease and Improve Survival.
Powers-James C, Morse M, Narayanan S, Ramondetta L, Lopez G, Wagner R, Cohen L. Powers-James C, et al. Curr Oncol Rep. 2024 Feb;26(2):147-163. doi: 10.1007/s11912-023-01467-5. Epub 2024 Jan 5. Curr Oncol Rep. 2024. PMID: 38180690 Review. - Meaning and Purpose (MaP) therapy in advanced cancer patients: a randomised controlled trial.
Kissane DW, Bobevski I, Appleton J, Murphy G, Laverty-Wilson A, Kessel P, Michael N, Chye R, Lethborg C. Kissane DW, et al. Support Care Cancer. 2023 Nov 30;31(12):734. doi: 10.1007/s00520-023-08189-1. Support Care Cancer. 2023. PMID: 38051407 Clinical Trial. - A Dutch Study of Remarkable Recoveries After Prayer: How to Deal with Uncertainties of Explanation.
Bendien E, Kruijthoff DJ, van der Kooi C, Glas G, Abma T. Bendien E, et al. J Relig Health. 2023 Jun;62(3):1731-1755. doi: 10.1007/s10943-023-01750-6. Epub 2023 Feb 4. J Relig Health. 2023. PMID: 36738396 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical